{
  "name": "Amgen",
  "slug": "amgen",
  "ticker": "AMGN",
  "fetched_at": "2026-01-31T12:27:01.961385+00:00",
  "news": [
    {
      "title": "Amgen gives up on its once-prized eczema drug - BioPharma Dive",
      "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPV3NpQ3EtcEk3R1Ytdy1DX19ST1J1S2ZUS1FoS2R3MXVmYVpuVzlKdi1XZ2RqU0tfRFlDdjI2elhLd0dJUGtlYkJjYUVsQ3VwbUpDenlXVWlJRmhMbE4zUnVudkpHdU8wZTEwaE1BSjUzell0S09EMHk5RDdyTnpaRFF2TzdIeEMzMlY5ZU0xNTNCTHVSRVVmWUdjWjUtYlA2Q1dJellpb1BkN1ZGaWc?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMirgFBVV95cUxPV3NpQ3EtcEk3R1Ytdy1DX19ST1J1S2ZUS1FoS2R3MXVmYVpuVzlKdi1XZ2RqU0tfRFlDdjI2elhLd0dJUGtlYkJjYUVsQ3VwbUpDenlXVWlJRmhMbE4zUnVudkpHdU8wZTEwaE1BSjUzell0S09EMHk5RDdyTnpaRFF2TzdIeEMzMlY5ZU0xNTNCTHVSRVVmWUdjWjUtYlA2Q1dJellpb1BkN1ZGaWc?oc=5\" target=\"_blank\">Amgen gives up on its once-prized eczema drug</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioPharma Dive</font>",
      "published": "2026-01-30T17:12:48+00:00",
      "source": "BioPharma Dive"
    },
    {
      "title": "Amgen exits $400M autoimmune pact after running vast program - Fierce Biotech",
      "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQX0JJNGxMMTVIY3FndkpvbkJ5WjNaWGhnb3BRNHVLTDk5aFhnM3o4WERSWUVSSTAycm4tTkhOZGhoVGVBVWZSeGpYZmlpNzc0anRrTlRDelh4ZVBYcndEajFLOGhSQlhEZ2VsQTNzRVFYRmhldVBrZVY4U0EtNkU0ZEhaOS1aVktVd0pndHZtR19rNFk3TEVsVkEydEktVzduWUZPOUNjdE9XSHRfbVRUMlRSdzdiaDZtTm5Z?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQX0JJNGxMMTVIY3FndkpvbkJ5WjNaWGhnb3BRNHVLTDk5aFhnM3o4WERSWUVSSTAycm4tTkhOZGhoVGVBVWZSeGpYZmlpNzc0anRrTlRDelh4ZVBYcndEajFLOGhSQlhEZ2VsQTNzRVFYRmhldVBrZVY4U0EtNkU0ZEhaOS1aVktVd0pndHZtR19rNFk3TEVsVkEydEktVzduWUZPOUNjdE9XSHRfbVRUMlRSdzdiaDZtTm5Z?oc=5\" target=\"_blank\">Amgen exits $400M autoimmune pact after running vast program</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Biotech</font>",
      "published": "2026-01-30T13:55:13+00:00",
      "source": "Fierce Biotech"
    },
    {
      "title": "Amgen Lawsuit And Eczema Drug Exit Reframe Risk And R&D Priorities - simplywall.st",
      "link": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPVE94UlNCc3p3X3ZjMFA5RWhJUmlGaG1LNFZ0SlNIS2h5bWV6Z1FGdE84OXNPT1VHU3V5VGlseVdQLXJJRmJTWDNtRGx1dl85cEpaRTFIYldXUEpoZ3BlYmxIMWNYZmtlX3c1eUJ4OHlaWWVsLWFFSTI1RmpXN1NsamQwYW9rOF9hTTBLTWJJWFdtLV85VXpRcmVUN1RIbXRkWENXS2tRNDlWU084amE0VHBwUlVUcW54LTJtZm5pMk5pWVZPYzBjTzhTRUhPbkp6clVhdWdR?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPVE94UlNCc3p3X3ZjMFA5RWhJUmlGaG1LNFZ0SlNIS2h5bWV6Z1FGdE84OXNPT1VHU3V5VGlseVdQLXJJRmJTWDNtRGx1dl85cEpaRTFIYldXUEpoZ3BlYmxIMWNYZmtlX3c1eUJ4OHlaWWVsLWFFSTI1RmpXN1NsamQwYW9rOF9hTTBLTWJJWFdtLV85VXpRcmVUN1RIbXRkWENXS2tRNDlWU084amE0VHBwUlVUcW54LTJtZm5pMk5pWVZPYzBjTzhTRUhPbkp6clVhdWdR?oc=5\" target=\"_blank\">Amgen Lawsuit And Eczema Drug Exit Reframe Risk And R&amp;D Priorities</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">simplywall.st</font>",
      "published": "2026-01-31T08:51:21+00:00",
      "source": "simplywall.st"
    },
    {
      "title": "EMA looks into 'data integrity' issue with Amgen's Tavneos - pharmaphorum",
      "link": "https://news.google.com/rss/articles/CBMigAFBVV95cUxQYnpPZlpvSXZkSERkb2o0aWc2RHViZm5TU0x0OTFRZVhEd2hhUjB0OWhaVTdiRlI2VmtkUEVzaTg1aGhIM28yd2Z5bnlrWUg3c1RoT043TUtfdWdmYmY1Qk9pYlFKVzFER2M4VGhCRnZDYU1UUmR3cmhYUXpOcnI0ZA?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMigAFBVV95cUxQYnpPZlpvSXZkSERkb2o0aWc2RHViZm5TU0x0OTFRZVhEd2hhUjB0OWhaVTdiRlI2VmtkUEVzaTg1aGhIM28yd2Z5bnlrWUg3c1RoT043TUtfdWdmYmY1Qk9pYlFKVzFER2M4VGhCRnZDYU1UUmR3cmhYUXpOcnI0ZA?oc=5\" target=\"_blank\">EMA looks into 'data integrity' issue with Amgen's Tavneos</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">pharmaphorum</font>",
      "published": "2026-01-30T13:44:43+00:00",
      "source": "pharmaphorum"
    },
    {
      "title": "Amgen backs out of OX40 pact with Kyowa - FirstWord Pharma",
      "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE50MXlWeHk5eUl3T09JaGtUSjhaZ1BJQXd5b2ZEdXptVTRMQ3ZzZzZhTFl6MDZnX0hlLU9qVEFzZ1lERUNJSjQzZTJFNjl3bDB0YW5J?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiU0FVX3lxTE50MXlWeHk5eUl3T09JaGtUSjhaZ1BJQXd5b2ZEdXptVTRMQ3ZzZzZhTFl6MDZnX0hlLU9qVEFzZ1lERUNJSjQzZTJFNjl3bDB0YW5J?oc=5\" target=\"_blank\">Amgen backs out of OX40 pact with Kyowa</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">FirstWord Pharma</font>",
      "published": "2026-01-30T17:02:15+00:00",
      "source": "FirstWord Pharma"
    },
    {
      "title": "CHMP thumbs-up Novo's semaglutide for MASH, as Amgen gets Tavneos re-review on data integrity concerns - Fierce Pharma",
      "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOSkQ1MlBselFFLWVvdDJKTl9iSGlHZVpUeXd2bTk1X0E4MVFlUGhfVzFuMkkwMDZENTNOYlIzSzBUQlhuRUc1R01EVmtwcmwyLV9acHhGcjdIYllmUHRKVVdyam80RGh1Qjlaclp2MXVBT3QzelFuaUV5OGNfbWw1MkF5NmdiNTNtcENpTXlBUzk0T3pqZ0NDRDdWVklWa1NRcldqZ1Zrckc1Z2RnN1NDS3M4cmZqRm1CTUN1RHVRN3ViOUk?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOSkQ1MlBselFFLWVvdDJKTl9iSGlHZVpUeXd2bTk1X0E4MVFlUGhfVzFuMkkwMDZENTNOYlIzSzBUQlhuRUc1R01EVmtwcmwyLV9acHhGcjdIYllmUHRKVVdyam80RGh1Qjlaclp2MXVBT3QzelFuaUV5OGNfbWw1MkF5NmdiNTNtcENpTXlBUzk0T3pqZ0NDRDdWVklWa1NRcldqZ1Zrckc1Z2RnN1NDS3M4cmZqRm1CTUN1RHVRN3ViOUk?oc=5\" target=\"_blank\">CHMP thumbs-up Novo's semaglutide for MASH, as Amgen gets Tavneos re-review on data integrity concerns</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Pharma</font>",
      "published": "2026-01-30T17:00:00+00:00",
      "source": "Fierce Pharma"
    },
    {
      "title": "National Pension Service Has $334.14 Million Stock Position in Amgen Inc. $AMGN - MarketBeat",
      "link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQQWpHUTJhemQyS3BKdmNlLUhKWERBTERJVGFjX3FfbHNxZUNMUFhmZ3JNZHZxeEh1aGFKNFR4NGtWb2dFQ0NuYmdXaXpRZFFJRWVMSHNJc2ZkdXhVcmVkb1ppN0t0N1RrbV9HalVVcFFDbkpkX05sQXlYcnk2SHBXMFh3MS1BWVlnTTBsSGp4LXRVNFpvVFliRzdFaWdtbzN4S0VaSXktSkV1TVRKZlZ6dnlEdENHMW0ycDVmTDBoVkZmVlh4d0dMMjNiMkNsazN0S3c?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQQWpHUTJhemQyS3BKdmNlLUhKWERBTERJVGFjX3FfbHNxZUNMUFhmZ3JNZHZxeEh1aGFKNFR4NGtWb2dFQ0NuYmdXaXpRZFFJRWVMSHNJc2ZkdXhVcmVkb1ppN0t0N1RrbV9HalVVcFFDbkpkX05sQXlYcnk2SHBXMFh3MS1BWVlnTTBsSGp4LXRVNFpvVFliRzdFaWdtbzN4S0VaSXktSkV1TVRKZlZ6dnlEdENHMW0ycDVmTDBoVkZmVlh4d0dMMjNiMkNsazN0S3c?oc=5\" target=\"_blank\">National Pension Service Has $334.14 Million Stock Position in Amgen Inc. $AMGN</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">MarketBeat</font>",
      "published": "2026-01-31T08:34:44+00:00",
      "source": "MarketBeat"
    },
    {
      "title": "Amgen Returns Eczema Drug To Kyowa Kirin On Marketability Doubts - Citeline News & Insights",
      "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNUVJ0R2Z4MnVuUC1Zbm5xS01nTk0tYTRVc1V2VXdVamwyWUwxX3BMelJNUE9MYU5sUVQ2ejdGeHBqS3p6TFppUTFlRWY5MlNDSWVlRVRCQXAwbnpMczlWbU13ZjkyY3hjSVVaVGpWc0hfejZ3MUJEOFNINDVycmNXUC1rS25OaFNKaE9kMjlTa1NTRFFGYllwT0h0cmVQRXZOVzN3dnM1dmxOWVA3ZXJOT3p1MS02ZFdha2ptcVFUdl9rZTA3cUFWb0ZfdzgtZmNPM2pWQ0V0clZiUkE?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNUVJ0R2Z4MnVuUC1Zbm5xS01nTk0tYTRVc1V2VXdVamwyWUwxX3BMelJNUE9MYU5sUVQ2ejdGeHBqS3p6TFppUTFlRWY5MlNDSWVlRVRCQXAwbnpMczlWbU13ZjkyY3hjSVVaVGpWc0hfejZ3MUJEOFNINDVycmNXUC1rS25OaFNKaE9kMjlTa1NTRFFGYllwT0h0cmVQRXZOVzN3dnM1dmxOWVA3ZXJOT3p1MS02ZFdha2ptcVFUdl9rZTA3cUFWb0ZfdzgtZmNPM2pWQ0V0clZiUkE?oc=5\" target=\"_blank\">Amgen Returns Eczema Drug To Kyowa Kirin On Marketability Doubts</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Citeline News & Insights</font>",
      "published": "2026-01-30T20:06:07+00:00",
      "source": "Citeline News & Insights"
    }
  ],
  "product_launches": [
    {
      "title": "A Fresh Look at Amgen (AMGN) Valuation After Key EU Drug Approval and Upcoming Clinical Data Releases - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPdXV6ZkFTSE1jV2hDZ0I2VlJTRDZvT1Z5T0toZUswZUE1WHk1YVI4dnNncUpBY3BDX0JJejBvdFB3VGx6ejNhaENaeVMtcE9Mc1diWUFIQXZtNVFyT1VId2FIQ2xSMHpyLVk1T0ljbmVCMnR2cXZjVXVIZDNMeHgwUTBVYw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMigwFBVV95cUxPdXV6ZkFTSE1jV2hDZ0I2VlJTRDZvT1Z5T0toZUswZUE1WHk1YVI4dnNncUpBY3BDX0JJejBvdFB3VGx6ejNhaENaeVMtcE9Mc1diWUFIQXZtNVFyT1VId2FIQ2xSMHpyLVk1T0ljbmVCMnR2cXZjVXVIZDNMeHgwUTBVYw?oc=5\" target=\"_blank\">A Fresh Look at Amgen (AMGN) Valuation After Key EU Drug Approval and Upcoming Clinical Data Releases</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-11-01T07:00:00+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "A Look at Amgen’s (AMGN) Valuation Following FDA Nod Expanding Repatha’s Patient Reach - simplywall.st",
      "link": "https://news.google.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?oc=5",
      "summary": "<a href=\"https://news.google.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?oc=5\" target=\"_blank\">A Look at Amgen’s (AMGN) Valuation Following FDA Nod Expanding Repatha’s Patient Reach</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">simplywall.st</font>",
      "published": "2025-09-08T07:00:00+00:00",
      "source": "simplywall.st"
    },
    {
      "title": "Amgen History - Amgen",
      "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE53MklERTNSbkNVaXhYQ3dPcEtDRU1uTW5mLUdxSGFtZ0wxMmFZSlQ1SnZkY1hZOFZ1RmRsZjNXMGYtM1hQXzl0R0NJSmtQLVJnYzlN?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiU0FVX3lxTE53MklERTNSbkNVaXhYQ3dPcEtDRU1uTW5mLUdxSGFtZ0wxMmFZSlQ1SnZkY1hZOFZ1RmRsZjNXMGYtM1hQXzl0R0NJSmtQLVJnYzlN?oc=5\" target=\"_blank\">Amgen History</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Amgen</font>",
      "published": "2020-12-12T03:24:17+00:00",
      "source": "Amgen"
    },
    {
      "title": "3 major patent losses this year — and a key strategy to fill the gaps - Pharma Voice",
      "link": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPNGpDZTgwdDRLOFozTU9HVGVzWWpkS1dXSEd4X1c0RzVVdktmbzUwVVhWSW01X3BkbGl5c084anVWeHVkX1FEU1pEMm13ZW91WlBwNE5CQVVmYURaaEFOREx0dk1fTTJyT01lYW1ZVXBOV2ZXTTdFamNYc2FVbTAyazJOeEVnNkszUXphcjI5blNXSV9wZ0tmcThR?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMimgFBVV95cUxPNGpDZTgwdDRLOFozTU9HVGVzWWpkS1dXSEd4X1c0RzVVdktmbzUwVVhWSW01X3BkbGl5c084anVWeHVkX1FEU1pEMm13ZW91WlBwNE5CQVVmYURaaEFOREx0dk1fTTJyT01lYW1ZVXBOV2ZXTTdFamNYc2FVbTAyazJOeEVnNkszUXphcjI5blNXSV9wZ0tmcThR?oc=5\" target=\"_blank\">3 major patent losses this year — and a key strategy to fill the gaps</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Pharma Voice</font>",
      "published": "2025-07-21T07:00:00+00:00",
      "source": "Pharma Voice"
    },
    {
      "title": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns - Seeking Alpha",
      "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5\" target=\"_blank\">Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Seeking Alpha</font>",
      "published": "2025-07-15T07:00:00+00:00",
      "source": "Seeking Alpha"
    }
  ],
  "stock": {
    "ticker": "AMGN",
    "currency": "USD",
    "latest": {
      "date": "2026-01-30",
      "close": 341.8800048828125
    },
    "history": [
      {
        "date": "2026-01-22",
        "close": 347.07000732421875
      },
      {
        "date": "2026-01-23",
        "close": 344.75
      },
      {
        "date": "2026-01-26",
        "close": 349.69000244140625
      },
      {
        "date": "2026-01-27",
        "close": 351.32000732421875
      },
      {
        "date": "2026-01-28",
        "close": 342.2200012207031
      },
      {
        "date": "2026-01-29",
        "close": 342.94000244140625
      },
      {
        "date": "2026-01-30",
        "close": 341.8800048828125
      }
    ],
    "name": "Amgen Inc."
  }
}